Latticework Capital Management has announced its acquisition of Catalina Research Institute (CRI).

CRI, based in Montclair, Calif., is a multidisciplinary clinical trials facility. Founded in 1997, the company specializes in the conduct of phase II through phase IV pharmaceutical drug studies.

Latticework, based in Dallas, makes control equity investments in the lower middle market. Founded in 2015, the firm focuses exclusively on healthcare, specifically the provider services, hospital/major facilities, life sciences/pharmaceutical (pharmaceutical services and contract manufacturing for medical equipment/devices) and non-reimbursement industries. Latticework prefers to make more substantial investments from a dollars perspective.

Terms of the acquisition were not disclosed.

Latticework also announced the formation of American Clinical Research Services Holdings, a clinical trial site management organization, via the acquisition of CRI.